Abstract
Background: The association between prediagnostic antibody responses to Fusobacterium nucleatum (F. nucleatum) and subsequent risk of colorectal cancer is not established. Methods: We conducted a nested case-control study of 8,126 participants in a consortium of 10 prospective cohorts in the United States. Results: Higher seroprevalence of any F. nucleatum antibody was observed among non-White participants (51.1%) compared with White participants (31.2%). We did not find any statistically significant association between seropositivity to any of the eight F. nucleatum proteins and colorectal cancer risk. Conclusions: Prediagnostic antibody responses to F. nucleatum proteins were not associated with the risk of colorectal cancer. Impact: Future studies may consider a more specific detection of the immunoglobulin isotypes or focus on examining F. nucleatum in stool or tissue samples.
Cite
CITATION STYLE
Lo, C. H., Blot, W. J., Teras, L. R., Visvanathan, K., Le Marchand, L., Haiman, C. A., … Song, M. (2021). Prediagnostic antibody responses to fusobacterium nucleatum proteins are not associated with risk of colorectal cancer in a large U.S. Consortium. Cancer Epidemiology Biomarkers and Prevention, 30(6), 1279–1282. https://doi.org/10.1158/1055-9965.EPI-20-1471
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.